The clinical utility of next-generation sequencing for bone and soft tissue sarcoma

References

• Spiguel A. Soft tissue sarcomas. Cancer Treat Res. 2014;162:203–223.
   PubMedGoogle Scholar
• Jo VY, Fletcher CDM. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology (Phila). 2014;46(2):95–104.
   Google Scholar
• Mertens F, Tayebwa J. Evolving techniques for gene fusion detection in soft tissue tumours. Histopathology. 2014;64(1):151–162.
   PubMed Web of Science ®Google Scholar
• Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 1995;13(7):1537–1545.
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–423.
   PubMed Web of Science ®Google Scholar
• Weiss MC, Blank A, Gitelis S, et al. Clinical benefit of next generation sequencing in soft tissue and bone sarcoma: Rush University medical center’s experience. J Clin Oncol. 2019; 37(15_suppl):e22552–e22552.
   Web of Science ®Google Scholar
• Boddu S, Walko CM, Bienasz S, et al. Clinical utility of genomic profiling in the treatment of advanced sarcomas: a single-center experience. J Clin Oncol Precis Oncol. 2018;2:1–8.
   PubMed Web of Science ®Google Scholar
• Cote GM, He J, Choy E. Next-generation sequencing for patients with sarcoma: a single center experience. Oncologist. 2018;23(2):234–242.
   PubMed Web of Science ®Google Scholar
• Groisberg R, Hong DS, Holla V, et al. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017; 8(24):39254–39267.
   PubMedGoogle Scholar
• Wilky BA, Villalobos VM. Emerging role for precision therapy through next-generation sequencing for sarcomas. J Clin Oncol Precis Oncol. 2018;2:1–4.
   PubMed Web of Science ®Google Scholar
• Gounder MM, Ali SM, Robinson V, et al. Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma. J Clin Oncol. 2017; 35(15_suppl):11001–11001.
   Web of Science ®Google Scholar
• Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031.
   PubMed Web of Science ®Google Scholar
• Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117(5):1049–1054.
   PubMed Web of Science ®Google Scholar
• Schwaederle M, Zhao M, Lee JJ, et al. Impact of precision medicine in diverse cancers: a Meta-Analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–3825.
   PubMed Web of Science ®Google Scholar
• Tsimberidou A-M, Wen S, Hong DS, et al. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014;20(18):4827–4836.
   PubMed Web of Science ®Google Scholar
• Al Baghdadi T, Halabi S, Garrett-Mayer E, et al. Palbociclib in patients with pancreatic and biliary cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. J Clin Oncol Precis Oncol. 2019; 3:1–8.
   PubMedGoogle Scholar
• Ahn ER, Mangat PK, Garrett-Mayer E, et al. Palbociclib in patients with non–small-cell lung cancer with CDKN2A alterations: results from the targeted agent and profiling utilization registry study. J Clin Oncol Precis Oncol. 2020; 4:757–766.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
   PubMed Web of Science ®Google Scholar
• Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014; 7(1):104–112.
   PubMed Web of Science ®Google Scholar
• Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111(51):E5564–5573.
   PubMed Web of Science ®Google Scholar